The growing threat to world health from antimicrobial resistance (AMR) is no stranger to the pages of Prescriber. We regularly cover the various warnings of and potential solutions to the problem – and this month Professor Dame Sally Davies, chief medical officer for England, has yet again pleaded for global action
Articles: 28.10 October 2017
Colic is common in the infant population but it can be challenging to diagnose and manage in the primary care setting. In this article, Dr Kanabar discusses how to reach a diagnosis of infantile colic and provides an overview of the current treatment options and their efficacy
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, are novel lipid-lowering agents that can produce a further substantial reduction in LDL cholesterol in patients who cannot reach target using standard therapy with statins and ezetimibe. This article examines the current approaches to lipid-lowering for primary and secondary prevention of cardiovascular disease and the place of these new agents in therapy.
With the number of biosimilar drugs being approved in the EU rising rapidly, the European Medicines Agency and the European Commission have jointly published a guide for healthcare professionals to provide reassurance on their safety and efficacy – but does it fall short of the rigorous analysis clinicians require
Drug repurposing has the potential to bring much-needed new treatments to the market quickly. However, despite many promising candidates, this approach is still underused, with funding and regulatory problems often impeding the development process.
NHS England and NHS Clinical Commissioners have been consulting on proposed new guidance for CCGs on items that should not routinely be prescribed in primary care owing to their “low clinical value”. The aim is to address unwarranted variation in prescribing and reduce NHS expenditure, but what will be the impact on patients and how do healthcare professionals feel about the plans
Eluxadoline (Truberzi) is an oral mixed opioid receptor agonist/antagonist licensed for the treatment of irritable bowel syndrome with diarrhoea in adults. This article examines its properties, efficacy in clinical trials and side effects